NOXXON PHARMA NV (ALNOX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALNOX - NL0012044762 - Common Stock
ALNOX.PA Key Statistics, Chart & Performance
The current stock price of ALNOX.PA is 0.041 EUR. In the past month the price decreased by -38.99%. In the past year, price decreased by -88.28%.
ALNOX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| ARGX.BR | ARGENX SE | 68.11 | 44.24B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.50B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| NANO.PA | NANOBIOTIX | N/A | 950.81M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 718.23M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About ALNOX.PA
Company Profile
NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
Company Info
NOXXON PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 13
Phone: 49307262470.0
NOXXON PHARMA NV / ALNOX.PA FAQ
Can you describe the business of NOXXON PHARMA NV?
NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
What is the stock price of NOXXON PHARMA NV today?
The current stock price of ALNOX.PA is 0.041 EUR. The price decreased by -18% in the last trading session.
What is the dividend status of NOXXON PHARMA NV?
ALNOX.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALNOX stock?
ALNOX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of NOXXON PHARMA NV (ALNOX.PA) based on its PE ratio?
NOXXON PHARMA NV (ALNOX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
Can you provide the number of employees for NOXXON PHARMA NV?
NOXXON PHARMA NV (ALNOX.PA) currently has 13 employees.
ALNOX.PA Technical Analysis
ALNOX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALNOX.PA. ALNOX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALNOX.PA Financial Highlights
Over the last trailing twelve months ALNOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 40.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.9% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALNOX.PA Forecast & Estimates
10 analysts have analysed ALNOX.PA and the average price target is 7.39 EUR. This implies a price increase of 17919.93% is expected in the next year compared to the current price of 0.041.